See you in court: Mallinckrodt takes on feds to fight $600M in back Acthar rebates

Mallinckrodt’s Acthar Gel is no stranger to controversy. Pricing critics, payers, and the feds have all targeted the controversial hormone injection. But now, Medicaid is hitting Acthar where it hurts most—in the pocketbook—and the company is more than happy to go to court.